MyMD Corporate Presentation October 2021 - Aging Related Diseases

MyMD is developing novel immunotherapies focused on aging, related diseases, and autoimmune diseases. The company has two drug candidates: MYMD-1, a clinical-stage immunometabolic regulator, and Supera-CBD, a preclinical patented synthetic cannabidiol derivative. Phase 2 clinical trials at Johns Hopkins University were planned for Q4 2021.